These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 8086621)
1. Absence of responsiveness to interferon-gamma but not to interleukin 2 and depressed recycling as natural killer cell abnormalities in childhood lymphohistiocytic syndrome. Yang FC; Yabuhara A; Koike K Int J Hematol; 1994 Jun; 59(4):273-80. PubMed ID: 8086621 [TBL] [Abstract][Full Text] [Related]
2. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism. Rook AH; Hooks JJ; Quinnan GV; Lane HC; Manischewitz JF; Macher AM; Masur H; Fauci AS; Djeu JY J Immunol; 1985 Mar; 134(3):1503-7. PubMed ID: 3918102 [TBL] [Abstract][Full Text] [Related]
3. A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. Yabuhara A; Yang FC; Nakazawa T; Iwasaki Y; Mori T; Koike K; Kawai H; Komiyama A J Rheumatol; 1996 Jan; 23(1):171-7. PubMed ID: 8838528 [TBL] [Abstract][Full Text] [Related]
4. Differential effects of recombinant human interferon-gamma and interleukin 2 on natural killer cell activity of peripheral blood in early human development. Ueno Y; Miyawaki T; Seki H; Matsuda A; Taga K; Sato H; Taniguchi N J Immunol; 1985 Jul; 135(1):180-4. PubMed ID: 3923100 [TBL] [Abstract][Full Text] [Related]
5. A recycling defect as a characteristic of natural killer cells in childhood acute lymphoblastic leukemia. Yabuhara A; Kawai H Pediatr Res; 1990 Dec; 28(6):572-8. PubMed ID: 2284152 [TBL] [Abstract][Full Text] [Related]
6. [Functional abnormalities of natural killer cells in childhood hemophagocytic syndrome]. Yang FC; Yabuhara A; Koike K; Komiyama A Nihon Rinsho Meneki Gakkai Kaishi; 1995 Feb; 18(1):36-44. PubMed ID: 7553037 [TBL] [Abstract][Full Text] [Related]
7. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL 2. Bonavida B; Katz J; Gottlieb M J Immunol; 1986 Aug; 137(4):1157-63. PubMed ID: 3488345 [TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of IL-2, IL-12 and IL-18 on cytolytic activity, perforin expression and IFN-gamma production of porcine natural killer cells. Pintaric M; Gerner W; Saalmüller A Vet Immunol Immunopathol; 2008 Jan; 121(1-2):68-82. PubMed ID: 17913242 [TBL] [Abstract][Full Text] [Related]
9. NK cell natural cytotoxicity and IFN-gamma production are not always coordinately regulated: engagement of DX9 KIR+ NK cells by HLA-B7 variants and target cells. Kurago ZB; Lutz CT; Smith KD; Colonna M J Immunol; 1998 Feb; 160(4):1573-80. PubMed ID: 9469412 [TBL] [Abstract][Full Text] [Related]
10. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Ménard C; Blay JY; Borg C; Michiels S; Ghiringhelli F; Robert C; Nonn C; Chaput N; Taïeb J; Delahaye NF; Flament C; Emile JF; Le Cesne A; Zitvogel L Cancer Res; 2009 Apr; 69(8):3563-9. PubMed ID: 19351841 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity. Hafner M; Falk W; Echtenacher B; Männel DN Eur Cytokine Netw; 1999 Dec; 10(4):541-8. PubMed ID: 10586121 [TBL] [Abstract][Full Text] [Related]
12. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells. Gaddy J; Broxmeyer HE Cell Immunol; 1997 Sep; 180(2):132-42. PubMed ID: 9341743 [TBL] [Abstract][Full Text] [Related]
13. Alterations in tumor necrosis factor-alpha, interferon-gamma, and interleukin-6 production by natural killer cell-enriched peripheral blood mononuclear cells in chronic alcoholism: relationship with liver disease and ethanol intake. Laso FJ; Lapeña P; Madruga JI; San Miguel JF; Orfao A; Iglesias MC; Alvarez-Mon M Alcohol Clin Exp Res; 1997 Oct; 21(7):1226-31. PubMed ID: 9347083 [TBL] [Abstract][Full Text] [Related]
14. Natural killer cell activity in the systemic connective tissue diseases. Gonzalez-Amaro R; Alcocer-Varela J; Alarcón-Segovia D J Rheumatol; 1988 Aug; 15(8):1223-8. PubMed ID: 3263500 [TBL] [Abstract][Full Text] [Related]
15. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation. Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930 [TBL] [Abstract][Full Text] [Related]
16. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620 [TBL] [Abstract][Full Text] [Related]
17. Development of natural killer cytotoxicity during childhood: marked increases in number of natural killer cells with adequate cytotoxic abilities during infancy to early childhood. Yabuhara A; Kawai H; Komiyama A Pediatr Res; 1990 Oct; 28(4):316-22. PubMed ID: 1700360 [TBL] [Abstract][Full Text] [Related]
18. Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption. Laso FJ; Madruga JI; Girón JA; López A; Ciudad J; San Miguel JF; Alvarez-Mon M; Orfao A Hepatology; 1997 May; 25(5):1096-100. PubMed ID: 9141423 [TBL] [Abstract][Full Text] [Related]
19. Carbohydrate consumption during cycling increases in vitro NK cell responses to IL-2 and IFN-gamma. McFarlin BK; Flynn MG; Hampton T Brain Behav Immun; 2007 Feb; 21(2):202-8. PubMed ID: 16889932 [TBL] [Abstract][Full Text] [Related]
20. Down-regulation of IL-18 receptor in cancer patients: its clinical significance. Kobashi K; Iwagaki H; Yoshino T; Morimoto Y; Kohka H; Kodama M; Nishibori M; Akagi T; Tanaka N Anticancer Res; 2001; 21(5):3285-93. PubMed ID: 11848485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]